Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumors

• Akeso secured China NMPA CDE clearance to start a Phase I trial of AK157D1, a B7-H3 antibody-drug conjugate, in advanced solid tumors.
• The candidate becomes Akeso’s third next-generation ADC to enter clinical development, supporting its IO2.0 and ADC2.0 oncology strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608210130PR_NEWS_USPR_____CN31197) on August 21, 2026, and is solely responsible for the information contained therein.